BRPI0510114B8 - cristais do composto 4-oxoquinolina, cristais misturados e composição farmacêutica - Google Patents

cristais do composto 4-oxoquinolina, cristais misturados e composição farmacêutica

Info

Publication number
BRPI0510114B8
BRPI0510114B8 BRPI0510114A BRPI0510114A BRPI0510114B8 BR PI0510114 B8 BRPI0510114 B8 BR PI0510114B8 BR PI0510114 A BRPI0510114 A BR PI0510114A BR PI0510114 A BRPI0510114 A BR PI0510114A BR PI0510114 B8 BRPI0510114 B8 BR PI0510114B8
Authority
BR
Brazil
Prior art keywords
crystals
pharmaceutical composition
oxoquinoline compound
crystal
mixed
Prior art date
Application number
BRPI0510114A
Other languages
English (en)
Inventor
Uehara Ideto
Kondo Kentaro
Ando Koji
Matsuda Koji
Satoh Motohide
Miyake Shuji
Motomura Takahisa
Matsuda Takashi
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35079161&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0510114(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of BRPI0510114A publication Critical patent/BRPI0510114A/pt
Publication of BRPI0510114B1 publication Critical patent/BRPI0510114B1/pt
Publication of BRPI0510114B8 publication Critical patent/BRPI0510114B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

cristal estável de composto 4-oxoquinolina. a presente invenção proporciona um cristal de 6-(3-cloro-2-fluorobenzil)-1-[(s)-1-hidroximetil-2-metilpropil]-7-metóxi-4-oxo-1,4-diidroquinolina-3-ácido carboxílico, que mostra um padrão de difração de raio-x de pó de picos de difração característicos em ângulos de difração 2(teta)(º) como medido por difratometria de raio-x de pó. o cristal da presente invenção é superior em estabilidade física e química.
BRPI0510114A 2004-05-20 2005-05-19 cristais do composto 4-oxoquinolina, cristais misturados e composição farmacêutica BRPI0510114B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004-150979 2004-05-20
JP2004150979 2004-05-20
PCT/JP2005/009604 WO2005113508A1 (en) 2004-05-20 2005-05-19 Stable crystal of 4-oxoquinoline compound

Publications (3)

Publication Number Publication Date
BRPI0510114A BRPI0510114A (pt) 2007-09-25
BRPI0510114B1 BRPI0510114B1 (pt) 2020-09-15
BRPI0510114B8 true BRPI0510114B8 (pt) 2021-05-25

Family

ID=35079161

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510114A BRPI0510114B8 (pt) 2004-05-20 2005-05-19 cristais do composto 4-oxoquinolina, cristais misturados e composição farmacêutica

Country Status (32)

Country Link
US (6) US7635704B2 (pt)
EP (4) EP1636190B1 (pt)
JP (1) JP3754064B2 (pt)
KR (1) KR20080064909A (pt)
CN (1) CN1956961B (pt)
AR (2) AR049280A1 (pt)
AU (1) AU2005245296B2 (pt)
BR (1) BRPI0510114B8 (pt)
CA (1) CA2566922C (pt)
CY (1) CY1113010T1 (pt)
DK (2) DK1636190T3 (pt)
ES (2) ES2388441T3 (pt)
FI (2) FI3281939T3 (pt)
FR (1) FR23C1040I1 (pt)
HK (1) HK1083341A1 (pt)
HR (2) HRP20231588T3 (pt)
HU (2) HUE064615T2 (pt)
IL (1) IL179250A0 (pt)
LT (1) LT3281939T (pt)
MX (1) MXPA06013405A (pt)
MY (1) MY134672A (pt)
NO (6) NO339223B1 (pt)
NZ (1) NZ551839A (pt)
PE (2) PE20120361A1 (pt)
PL (2) PL1636190T3 (pt)
PT (2) PT1636190E (pt)
RS (2) RS52375B (pt)
RU (1) RU2330845C1 (pt)
SI (2) SI1636190T1 (pt)
TW (1) TWI329015B (pt)
WO (1) WO2005113508A1 (pt)
ZA (1) ZA200610647B (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6891227B2 (en) 2002-03-20 2005-05-10 International Business Machines Corporation Self-aligned nanotube field effect transistor and method of fabricating same
DE60329318D1 (de) * 2002-11-20 2009-10-29 Japan Tobacco Inc 4-oxochinolinverbindungen und deren verwendung als hiv-integrase-inhibitoren
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
WO2007063869A1 (ja) * 2005-11-30 2007-06-07 Japan Tobacco Inc. 高純度キノロン化合物の製造方法
US20090233964A1 (en) * 2005-12-30 2009-09-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
AU2013203476C1 (en) * 2005-12-30 2016-11-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
KR20160074018A (ko) * 2005-12-30 2016-06-27 길리애드 사이언시즈, 인코포레이티드 Ｈｉｖ 인테그라제 억제제의 약동학을 개선하기 위한 방법
US20090018162A1 (en) * 2006-02-01 2009-01-15 Yuji Matsuzaki Use of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or salt thereof for treating retrovirus infection
WO2007092802A1 (en) * 2006-02-09 2007-08-16 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and gs 9137
CA2645119C (en) 2006-03-06 2012-01-24 Japan Tobacco Inc. Method for producing 4-oxoquinoline compound
IN2014CN00532A (pt) 2006-03-06 2015-04-03 Japan Tobacco Inc
RS54237B9 (sr) 2006-07-07 2019-07-31 Gilead Sciences Inc Modulatori farmakokinetičkih svojstava terapeutika
WO2008033836A2 (en) 2006-09-12 2008-03-20 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
AR065439A1 (es) 2007-02-23 2009-06-10 Gilead Sciences Inc Derivados de tiazoles 1,3 no condensados,composiciones farmaceuticas que los contienen y usos como agentes antivirales, en particular anti hiv.
SG182228A1 (en) * 2007-06-29 2012-07-30 Gilead Sciences Inc Therapeutic compositions and uses thereof
US20100331331A1 (en) * 2007-06-29 2010-12-30 Therapeutic Compositons And Use Thereof Therapeutic compositions and the use thereof
AR068403A1 (es) * 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa
ES2553897T3 (es) 2008-05-02 2015-12-14 Gilead Sciences, Inc. El uso de partículas de vehículo sólido para mejorar la procesabilidad de un agente farmacéutico
SG2014007744A (en) 2009-02-06 2014-05-29 Gilead Sciences Inc Tablets for combination therapy
WO2010137032A2 (en) * 2009-05-14 2010-12-02 Matrix Laboratories Ltd. Novel polymorphic forms of elvitegravir and its pharmaceutically acceptable salts
WO2011004389A2 (en) * 2009-06-18 2011-01-13 Matrix Laboratories Ltd An improved process for the preparation of elvitegravir
CN102212032B (zh) * 2011-04-20 2013-07-31 复旦大学 一种5-羟基喹诺酮类衍生物及其制备方法和用途
US10071957B2 (en) 2012-07-06 2018-09-11 Genentech, Inc. N-substituted benzamides and methods of use thereof
PT2880017T (pt) 2012-08-03 2016-12-14 Gilead Sciences Inc Processo e intermediários para preparar inibidores da integrase
CN103819402B (zh) * 2012-11-17 2016-03-30 上海迪赛诺化学制药有限公司 埃替拉韦中间体及其制备方法和应用
CN103864682B (zh) * 2012-12-18 2016-12-28 上海迪赛诺化学制药有限公司 一种制备iii型埃替拉韦晶体的方法
SG11201504857SA (en) 2012-12-21 2015-07-30 Gilead Sciences Inc Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
NO2865735T3 (pt) 2013-07-12 2018-07-21
CA2916993C (en) 2013-07-12 2019-01-15 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
CN105315203A (zh) * 2014-06-06 2016-02-10 上海迪赛诺化学制药有限公司 一种v型埃替拉韦晶体及其制备方法
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (pt) 2014-06-20 2018-06-23
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
PL3277691T3 (pl) 2015-04-02 2019-07-31 Gilead Sciences, Inc. Policykliczne związki karbamoilopirydonowe i ich zastosowanie farmaceutyczne
CN106008195B (zh) * 2016-05-19 2018-08-03 绍兴文理学院 一种2，4-二氟-5-碘苯甲酸的制备方法
EP3984536A1 (en) * 2020-10-19 2022-04-20 Centre national de la recherche scientifique Inhibition of the hiv-1 replication by compounds directed against a new target of the viral cycle

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3472859A (en) * 1966-11-01 1969-10-14 Sterling Drug Inc 1-alkyl-1,4-dihydro-4-oxo-3 quinoline-carboxylic acids and esters
JPS567162B1 (pt) 1970-09-14 1981-02-16
JPS4826772A (pt) 1971-08-11 1973-04-09
JPS6450979A (en) 1987-08-21 1989-02-27 Hitachi Shipbuilding Eng Co Method for discriminating whistle sound
JPH0651229B2 (ja) 1989-07-31 1994-07-06 新日本製鐵株式会社 プラズマアーク溶接方法および装置
IL100555A (en) 1991-02-07 2000-08-31 Hoechst Marion Roussel Inc N-substituted quinoline derivatives their preparation their use for the preparation of medicaments and the pharmaceutical compositions containing them
JP2993316B2 (ja) 1992-05-27 1999-12-20 宇部興産株式会社 アリール基又は複素芳香環基置換アミノキノロン誘導体及びエイズ治療剤
NO304832B1 (no) 1992-05-27 1999-02-22 Ube Industries Aminokinolonderivater samt middel mot HIV
JPH06199835A (ja) 1993-01-08 1994-07-19 Hokuriku Seiyaku Co Ltd ８−ジフルオロメトキシキノリン−３−カルボン酸誘導体
JPH06271568A (ja) 1993-03-22 1994-09-27 Hokuriku Seiyaku Co Ltd ７−フェニルピペラジニルキノリン−３−カルボン酸誘導体
JP2930539B2 (ja) 1994-07-18 1999-08-03 三共株式会社 トリフルオロメチルキノリンカルボン酸誘導体
EP0773214A4 (en) 1994-07-18 1998-04-15 Ube Industries TRIFLUORMETHYLQUINOLINE CARBONIC ACID DERIVATIVES
JPH0826772A (ja) 1994-07-22 1996-01-30 Sony Corp 融着用ガラス、その製造方法及び製造装置、並びに磁気ヘッドの製造方法
DK0892801T3 (da) 1996-04-12 2002-04-22 Us Gov Health & Human Serv Acridon-afledte forbindelser, der er anvendelige som antineoplastiske og antiretrovirale midler
FR2761687B1 (fr) * 1997-04-08 2000-09-15 Centre Nat Rech Scient Derives de quinoleines, possedant notamment des proprietes antivirales, leurs preparations et leurs applications biologiques
JP3776203B2 (ja) 1997-05-13 2006-05-17 第一製薬株式会社 Ｉｃａｍ−１産生阻害剤
GB9721964D0 (en) 1997-10-16 1997-12-17 Pfizer Ltd Isoquinolines
US6399629B1 (en) 1998-06-01 2002-06-04 Microcide Pharmaceuticals, Inc. Efflux pump inhibitors
US6248736B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents
US6248739B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company Quinolinecarboxamides as antiviral agents
PE20011349A1 (es) 2000-06-16 2002-01-19 Upjohn Co 1-aril-4-oxo-1,4-dihidro-3-quinolincarboxamidas como agentes antivirales
US6559145B2 (en) 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
JP2004517860A (ja) 2000-10-12 2004-06-17 メルク　エンド　カムパニー　インコーポレーテッド Ｈｉｖインテグラーゼ阻害薬として有用なアザ−およびポリアザ−ナフタレニルカルボキサミド類
AU2002230392A1 (en) 2000-10-12 2002-05-15 Merck & Co., Inc. AZA-and polyaza-naphthalenyl ketones useful as HIV integrase inhibitors
BR0207809A (pt) 2001-03-01 2004-03-09 Shionogi & Co Compostos heteroarila contendo nitrogênio possuindo atividade inibidora contra integrase de hiv
JP2002293745A (ja) 2001-03-29 2002-10-09 St Marianna Univ School Of Medicine 慢性関節リウマチ治療剤
US20030138483A1 (en) * 2001-05-25 2003-07-24 Sergio Petriconi Soft elastic capsules and compositions thereof
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
FR2827600A1 (fr) 2001-07-20 2003-01-24 Lipha Derives acides de quinolone et leurs applications en therapeutique
JP4035765B2 (ja) 2002-10-31 2008-01-23 横河電機株式会社 フーリエ変換型赤外線分光計
JP3567162B1 (ja) 2002-11-20 2004-09-22 日本たばこ産業株式会社 ４−オキソキノリン化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用
DE60329318D1 (de) 2002-11-20 2009-10-29 Japan Tobacco Inc 4-oxochinolinverbindungen und deren verwendung als hiv-integrase-inhibitoren
US7531554B2 (en) * 2004-05-20 2009-05-12 Japan Tobacco Inc. 4-oxoquinoline compound and use thereof as HIV integrase inhibitor
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
EP2229945A1 (en) 2004-05-21 2010-09-22 Japan Tobacco, Inc. Combinations comprising a 4-isoquinolone derivative and anti-HIV agents

Also Published As

Publication number Publication date
ES2960824T3 (es) 2024-03-06
US20190185433A1 (en) 2019-06-20
EP3281939B1 (en) 2023-10-18
EP4299563A3 (en) 2024-02-28
ES2388441T3 (es) 2012-10-15
PL3281939T3 (pl) 2024-03-18
IL179250A0 (en) 2007-03-08
US20150361044A1 (en) 2015-12-17
PT1636190E (pt) 2012-08-20
CY1113010T1 (el) 2016-04-13
FIC20240008I1 (fi) 2024-03-20
NO339223B1 (no) 2016-11-21
RS64845B1 (sr) 2023-12-29
HUE064615T2 (hu) 2024-04-28
SI3281939T1 (sl) 2024-02-29
PE20060358A1 (es) 2006-05-12
HUS2400006I1 (hu) 2024-04-28
AU2005245296A1 (en) 2005-12-01
DK1636190T3 (da) 2012-09-24
FR23C1040I1 (fr) 2023-12-29
NO20190051A1 (no) 2007-02-07
MXPA06013405A (es) 2007-03-01
BRPI0510114B1 (pt) 2020-09-15
JP3754064B2 (ja) 2006-03-08
TWI329015B (en) 2010-08-21
FI3281939T3 (fi) 2023-10-23
LT3281939T (lt) 2023-11-27
HRP20120681T1 (hr) 2012-09-30
US20060030710A1 (en) 2006-02-09
EP2514746A1 (en) 2012-10-24
NO20200873A1 (no) 2007-02-07
MY134672A (en) 2007-12-31
AR049280A1 (es) 2006-07-12
CN1956961B (zh) 2010-05-26
NO20230913A1 (no) 2007-02-07
NO20161297A1 (no) 2007-02-07
PT3281939T (pt) 2023-11-22
RS52375B (en) 2012-12-31
AU2005245296B2 (en) 2010-08-12
CN1956961A (zh) 2007-05-02
PL1636190T3 (pl) 2012-10-31
US20100204271A1 (en) 2010-08-12
TW200600097A (en) 2006-01-01
CA2566922C (en) 2011-01-11
KR20080064909A (ko) 2008-07-09
EP1636190B1 (en) 2012-06-27
DK3281939T3 (da) 2024-01-22
WO2005113508A1 (en) 2005-12-01
US8981103B2 (en) 2015-03-17
NO20065790L (no) 2007-02-07
RU2330845C1 (ru) 2008-08-10
HK1083341A1 (en) 2006-06-30
US20220235009A1 (en) 2022-07-28
AR096100A2 (es) 2015-12-09
SI1636190T1 (sl) 2012-09-28
PE20120361A1 (es) 2012-05-03
NO20220690A1 (no) 2007-02-07
HRP20231588T3 (hr) 2024-03-15
ZA200610647B (en) 2008-06-25
NO347902B1 (no) 2024-05-06
US7635704B2 (en) 2009-12-22
NZ551839A (en) 2009-11-27
US20180029989A1 (en) 2018-02-01
CA2566922A1 (en) 2005-12-01
BRPI0510114A (pt) 2007-09-25
EP4299563A2 (en) 2024-01-03
JP2006001927A (ja) 2006-01-05
EP3281939A1 (en) 2018-02-14
EP1636190A1 (en) 2006-03-22

Similar Documents

Publication Publication Date Title
BRPI0510114B8 (pt) cristais do composto 4-oxoquinolina, cristais misturados e composição farmacêutica
RS50599B (sr) KRISTALNI OBLIK BETA-d IVABRADIN HLORHIDRATA, POSTUPAK NJEGOVE IZRADE I FARMACEUTSKE SMEŠE KOJE GA SADRŽE
RS50600B (sr) Kristalni oblik gama - d ivabradin hlorhidrata, postupak njegove izrade i farmaceutske smeše koje ga sadrže
SG170069A1 (en) Quinoline derivatives
CR20140392A (es) Dihidropirazolonas sustituidas
BR112014025564A8 (pt) composto heterocíclico contendo nitrogênio ou sal do mesmo
IN2012DN03328A (pt)
BRPI0507574A (pt) piridazinonas como antagonistas de alfa 4 integrinas
BR112013000254A2 (pt) derivados heterocíclicos 1-fenil-substituídos e seu uso como moduladores do receptor de prostaglandina d2
MXPA06009475A (es) Derivados de quinazolina y usos terapeuticos de los mismos.
UY33539A (es) Compuestos químicos alk
BRPI0900983A2 (pt) compostos de diometina, processo para sua preparação e composições farmacêuticas contendo os mesmos
MY175373A (en) Crystal form of phenylamino pyrimidine derivatives
DE602006004882D1 (de) Azabicycloä3.1.0ühexylphenylderivate als modulatoren von dopamin-d3-rezeptoren
DOP2006000062A (es) Derivados de acido pirimidincarboxilico y su uso
DE602006009789D1 (de) Acetylenderivate
WO2009021965A3 (en) Substituted quinoline derivatives as h1 receptor antagonists
WO2009121535A3 (en) Antiproliferative compounds and therapeutic uses thereof
BRPI0511999A (pt) compostos como antagonistas de ccr5
MX2009014001A (es) Derivados de isoxazol-imidazol.
WO2008074803A8 (en) 4-benzyl-l ( 2h) -phthalazinones as h1 receptor antagonists
MX2012008328A (es) Derivados de pirazina.
BRPI0417268A (pt) benzimidazóis que contêm morfolinila, como inibidores da replicação de vìrus sinciciais respiratórios
DK1869038T3 (da) Substituerede 5,6,7,8-tetrahydro-imidazol[1,2-a]pyridin-2-ylamin-forbindelser og deres anvendelse til fremstilling af lægemidler
BRPI0507321A (pt) derivados de 7-amino-4-quinolona-3-ácido carboxìlico substituìdos com cicloalquila, processos para produção dos mesmos e uso dos mesmos como medicamento

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/05/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25G Requested change of headquarter approved

Owner name: JAPAN TOBACCO, INC. (JP)